Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2022 Earnings Presentation
18 slides from Bactiguard Holding Ab's earnings presentation, Jul 14, 2022
Slide 1: Investor presentation Q2 2022
Investor presentation Q2 2022 14 July, 2022 Anders Göransson, CEO Carin Jakobson, CFO
Slide 2: Healthcare associated infections affect 1 in 10 patients
”The urinary tract infection was the beginning of the end for my friend” 1 in every 10 patients worldwide affected by healthcare associated infections 1. Source: Debate article Sundsvall Tidning 2022-02-10 2
Slide 3: Bactiguard's vision: Keeping people safe from infections
Bactiguard’s Bactiguard’svision: vision:Keeping Keepingpeople peoplesafe safefrom frominfections infections Keeping people safe from infections 3
Slide 4: Bactiguard – second quarter 2022
Bactiguard – second quarter 2022 Key Financials, Q2 2022 (Q2 2021) Revenue EBITDA Net Profit Operating cash flow MSEK 59.9 (46.0) • License 36.2 (31.6) MSEK -3.8 (1.8) MSEK -14.8 (-10.0) MSEK -1.9 (5.5) • BIP revenues 15.6 (13.3) Strong revenue growth of 30%, adjusted for currency effects 13% compar
Slide 5: Business Highlights – License revenue
Business Highlights – License revenue Another quarter with strong BD revenue and first revenues from Dentsply Sirona Q2 2022: Q2 2022: MSEK 28,0 (22,2) MSEK 8,2 (9,3) + 26%* - 12%* • The underlying business is stable on an • Fees for development work, contract manufacturing and annual basis – back t
Slide 6: Significant acceleration in the licence portfolio in recent years
Significant acceleration in the licence portfolio in recent years 1990 2019 2022 • Foley catheters • Trauma implants • Dental • Hips and knees • Sports medicine • Craniomaxillofacial • Thorax applications Additional licence agreements signed with Smartwise in Sweden in 2017 and with Well Lead in Chi
Slide 7: Global partnership with Dentsply Sirona
Dental Global partnership with Dentsply Sirona Bactiguard enters development agreement in the dental field • Development phase ─ USD 0.9 million in development and milestone fees (approx. 1 year) • Optional License agreement ─ USD 1.1 million in milestone payments, contingent on regulatory approvals
Slide 8: Dentsply Sirona - a major global player in the dental field
Dental Dentsply Sirona - a major global player in the dental field Example: Dental implants market Global marketshare 2021 Other Straumann 16% 41% Nobel 16% Biocare 13% 5% 9% Zimmer Dentsply Biomet Sirona Source: Dentsply Sirona Homepage, Global Data 2021 Osstem 8
Slide 9: Business Highlights – Bactiguard product portfolio
Business Highlights – Bactiguard product portfolio Strong growth in focus areas: BIP Urinary Catheters and Wound Care • Strong growth in focus products, amplified by a BACTIGUARD BIP PORTFOLIO positive currency effect • Momentum in BIP Foley (Urinary catheters) - more than doubled compared to LY Q2
Slide 10: Bactiguards technology – effective and biocompatible
Bactiguards technology – effective and biocompatible Recently published study highlights Bactiguards good blood compability vs other coated CVCs https://www.nature.com/articles /s41598-022-12564-zm) 10
Slide 11: Right timing to fuel growth
Right timing to fuel growth 1 2 3 Strong clinical evidence Capital for growth Commercial capabilities • >200 million catheters used with no • > 220 mSEK raised during the fall of • Strengthened commercial capabilities reported adverse event 2021 to fund a fact based, focused growth for continued exp
Slide 12: Rolling 12-month revenue
Rolling 12-month revenue • BD license increased 26% • BIP revenues growth mainly driven by BIP foleys and Wound Care. • New license revenue related to Zimmer Biomet and Dentsply Sirona 12
Slide 13: Financial overview
Financial overview Amounts in TSEK 2022 2021 2022 2021 2021 2021/22 Jan-June 2022 vs Jan-Jun Apr-Jun Apr-Jun Jan-Jun Jan-Jun Full year RTM 2021 Revenues 59,9 46,0 115,1 87,8 179,0 206,4 • Revenue MSEK 115 (88) an EBITDA -3,8 1,8 -7,8 3,7 -7,2 -18,8 increase of 30% though EBIITA margin % -6,4% 4,0% -
Slide 14: Cash flow and liquidity
Cash flow and liquidity • Cash flow from operating activities was -1.8 MSEK for Q2-2022. Due to investments in growth strategy. • SEB Overdraft facility unutilized, compared to 2021 0.0 (-14.4) MSEK • Available liquidity incl. overdraft facility 232.3 (54.4) MSEK * New share issue of MSEK 228 before
Slide 15: Global outlook
Global outlook Covid-19 and Ukraine • 554 million confirmed cases of Covid-19 • 6,4 million deaths • 12 billion vaccine doses have been administered 2020 2021 2022 • Bactiguard does not operate and has no • Covid-19 is still impacting globally suppliers in Russia or Ukraine. Not • Recent development
Slide 16: Ten reasons to invest in Bactiguard
Bactiguard infection prevention – Safe and Effective Ten reasons to invest in Bactiguard Long-term owners and 10 1 Contribution to the UN’s Global dedicated management Sustainable Development Goal. 2 Bactiguard technology Growth ambition 9 - effective and safe Financial Target 2026: • Revenue >1 bil
Slide 17: Questions & Answers
Questions & Answers Anders Göransson Carin Jakobson CEO CFO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com carin.jakobson@bactiguard.com 17
Slide 18: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside 18 18